Steven Glazerman, Larissa Campuzano, Nancy Murray
Education Experiments in Latin America: Empirical Evidence to Guide Evaluation Design
Evaluation review
30day mortality systemic anticancer therapy sact suggested quality indicator primarily measuring use chemotherapy towards end life utility across different cancer types unclear especially using immunotherapy targeted therapies retrospective study included patients diagnosis lung cancer received palliativeintent sact australian metropolitan cancer center 2015 2022 using prospectively maintained lung cancer database patient disease treatment characteristics evaluated annual 30day mortality rates following sact 1072 patients identified annual 30day mortality rate palliativeintent sact lung cancer ranged 9 15 significant variance treatment types calculated rates 30day mortality higher longer reporting time periods used patients died within 30 days sact likely received targeted therapies immunotherapy final line treatment poorer performance status diagnosis received multiple lines treatment data support differential interpretation 30day mortality quality assurance especially regard lung cancer consistency population reporting time periods accounting treatment type crucial 30day mortality utilized cancer care performance quality indicator relevance quality care questionable lung cancer setting